IIM Clinical Trials in Wuhan, Hubei
2 recruitingWuhan, Hubei, China
Showing 1–2 of 2 trials
Recruiting
Phase 1
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Neuromyelitis Optica Spectrum Disorder (NMOSD)Multiple Sclerosis (MS)Myasthenia Gravis (MG)+4 more
Tongji Hospital6 enrolled1 locationNCT07526493
Recruiting
Early Phase 1
GC012F Injection in Refractory Idiopathic Inflammatory Myopathy
Idiopathic Inflammatory Myopathy (IIM)
Daishi Tian12 enrolled1 locationNCT07086404